teladoc glp 1 💊 For the past few years, GLP-1 receptor agonists have dominated the conversation around weight management. This month, the MHRA approved the UK's first oral GLP-1 receptor agonist tablet for… GLP-1 End Game: Should Deprescribing

PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs

Need to come up with something here

Nishinaka, Y., et al., Redox control of cellular function by thioredoxin

[1] [2] Patients with these conditions should not receive these medications, and alternative treatments for diabetes or weight management should be considered